As of June 2023 Intra-Cellular Therapies has a market cap of $5.88 Billion. This makes Intra-Cellular Therapies the world's 2170th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2023 | $5.88 B | 17.37% |
2022 | $5.01 B | 17.54% |
2021 | $4.26 B | 66.64% |
2020 | $2.55 B | 34.35% |
2019 | $1.90 B | 204.59% |
2018 | $0.62 B | -20.88% |
2017 | $0.79 B | 21.04% |
2016 | $0.65 B | -71.87% |
2015 | $2.32 B | 345.85% |
2014 | $0.52 B | 17.48% |
2013 | $0.44 B |
On Jun 2nd, 2023 the market cap of Intra-Cellular Therapies was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
![]() Xencor XNCR | $1.67 B | -71.57% | ๐บ๐ธ USA |
![]() MediciNova MNOV | $0.10 B | -98.17% | ๐บ๐ธ USA |
![]() Curis CRIS | $82.99 M | -98.59% | ๐บ๐ธ USA |